1501P - Safety and efficacy of pazopanib (PAZ) in advanced soft tissue carcinoma (aSTS) by prior lines of therapy, age, and dose modifications: PALETTE sub...

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Soft Tissue Sarcomas
Sarcoma
Presenter Axel Le Cesne
Citation Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387
Authors A. Le Cesne1, S. Bauer2, G.D.S. Demetri3, W.T.A. van der Graaf4, G. Han5, L. Dezzani5, Q. Ahmad5, H. Gelderblom6
  • 1Medical Oncology & Surgery, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
  • 2Dept. Of Medical Oncology, University Hospital Essen Westdeutsches Tumorzentrum, 45122 - Essen/DE
  • 3Center For Sarcoma And Bone Oncology, Dana-Farber Cancer Institute and Ludwig Center, Harvard Medical School, 02215 - Boston/US
  • 4Sarcoma Unit, The Institute of Cancer Research and the Royal Marsden Hospital , Sutton/GB
  • 5Novartis Oncology, Novartis Pharmaceuticals, 07936-1080 - East Hanover/US
  • 6Medical Oncology, Leiden University Medical Center (LUMC), Leiden/NL

Abstract

Background

PALETTE was a randomized phase 3 trial (NCT00753688) that demonstrated single-agent activity of PAZ in advanced STS (aSTS). We evaluated the relationship between age, prior lines of therapy, and dose modifications on the safety and efficacy of PAZ in aSTS.

Methods

Median progression-free survival (mPFS) was evaluated in subgroups of prior lines of therapy (1 prior line; 2+ prior lines), age (

Results

A total of 246 patients received pazopanib in the PALETTE study. Median PFS and median overall survival (OS) were longer in patients receiving PAZ who had only 1 prior line of therapy vs 2+ prior lines of therapy (mPFS, 24.7 vs 18.9 weeks [Table]; OS, 13.7 vs 11.3 months). In patients receiving PAZ, mPFS was similar in ages

Conclusions

Longer mPFS was observed in patients receiving PAZ following only 1 line of therapy. Additionally, mPFS with PAZ was maintained regardless of patient age or if dose modification was required to manage toxicity.

Clinical trial identification

NCT00753688

Legal entity responsible for the study

Novartis Pharmaceutical Corporation

Funding

Novartis Pharmaceutical Corporation

Disclosure

A. Le Cesne: Pharmamar, Lilly, Pfizer, Novartis, Amgen. S. Bauer: Research support: Novartis, Blueprint Medicines, Ariad. Ad board: GSK, Novartis, Pfizer, Bayer, Fresenius, Lilly, Blueprint Medicines, Deciphera. CME-Honoraria: Pharmamar, GSK, Bayer, Novartis. Travel support: Pharmamar, Bayer. G.D.S. Demetri: Grants and personal fees from Novartis, during the conduct of the study; grants and personal fees from Janssen, Eisai, Eli Lilly and PharmaMar, outside the submitted work. W.T.A. van der Graaf: Research grants: GSK, Novartis. Advisory board: Bayer. G. Han, L. Dezzani, Q. Ahmad: Employee of Novartis. H. Gelderblom: Grants to institution LUMC, during the conduct of the study.